依法韦仑与洛匹那韦/利托那韦组成的无核苷类逆转录酶抑制剂高效抗逆转录病毒治疗方案在HIV-1感染儿童中的安全性和疗效
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
作者信息
Fraaij Pieter L A, Neubert Jennifer, Bergshoeff Alina S, van Rossum Annemarie M C, Hartwig Nico G, Schroten Horst, Korn Klaus, Burger David M, de Groot Ronald, Niehues Tim
机构信息
Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, the Netherlands.
出版信息
Antivir Ther. 2004 Apr;9(2):297-9.
We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.
我们研究了一种不含核苷类逆转录酶抑制剂（NRTI）的治疗方案，用于治疗感染耐NRTI的HIV-1儿童。洛匹那韦/利托那韦与依非韦伦联合用药可长期抑制HIV-1水平，尽管此前曾广泛使用NRTI（超过4年），但仍使CD4+T细胞数量显著增加。观察到的副作用除血脂异常外均为短暂性。
Zotero 插件